Disc Medicine Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| · Year EndedDecember 31, | |||||
|---|---|---|---|---|---|
| · 2023 · · 2022 | |||||
| Operating expenses: · · | |||||
| Research and development | | $69,264 | | $33,437 | |
| General and administrative | | 21,861 | | 14,038 | |
| Total operating expenses | | 91,125 | | 47,475 | |
| Loss from operations | | (91,125) | | (47,475) | |
| Other income (expense), net: | | | |||
| Interest income | | 14,797 | | 709 | |
| Change in fair value of derivative liability | | — | | (61) | |
| Other expense | | (2) | | — | |
| Total other income (expense), net | | 14,795 | | 648 | |
| Loss before income taxes | | (76,330) | | (46,827) | |
| Income tax expense | (99) | — | |||
| Net loss and comprehensive loss | | $(76,429) | | $(46,827) | |
| Net loss attributable to common stockholders-basic and diluted | | $(76,429) | | $(46,827) | |
| Weighted-average common shares outstanding-basic and diluted | | 22,315,877 | 1,039,490 | ||
| Net loss per share attributable to common stockholders-basic and diluted | | $(3.42) | | $(45.05) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.